Industry
Drug Manufacturers - Specialty & Generic
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Loading...
Open
7.05
Mkt cap
9.3M
Volume
11K
High
7.30
P/E Ratio
-0.02
52-wk high
82.00
Low
6.70
Div yield
N/A
52-wk low
6.70
Portfolio Pulse from Benzinga Newsdesk
August 21, 2024 | 3:50 pm
Portfolio Pulse from Benzinga Newsdesk
August 21, 2024 | 11:25 am
Portfolio Pulse from Benzinga Newsdesk
August 20, 2024 | 12:55 pm
Portfolio Pulse from Benzinga Newsdesk
August 19, 2024 | 11:50 pm
Portfolio Pulse from Vandana Singh
August 19, 2024 | 12:56 pm
Portfolio Pulse from Benzinga Newsdesk
August 19, 2024 | 12:12 pm
Portfolio Pulse from Benzinga Newsdesk
August 19, 2024 | 11:05 am
Portfolio Pulse from Benzinga Newsdesk
August 16, 2024 | 11:07 am
Portfolio Pulse from Avi Kapoor
August 01, 2024 | 6:34 pm
Portfolio Pulse from Avi Kapoor
August 01, 2024 | 5:18 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.